Elevated mutation burden, observed in 32% (8/25) of tumors, was associated with systemic activation of HER3 (ERBB3) signaling, which may represent a potential therapeutic target for patients who have progressed following immunotherapy and/or whose tumor demonstrates high mutation burden. The gene discussed is ERBB3; the disease is neoplasm.